Kornimate/medical-research-clean huggingface dataset:
analysis of new salivary biomarkers to evaluate excessive diurnal sleepiness in children with hypersomnia

Conditions: Hypersomnia; Sleepiness, Excessive Daytime

Summary: excessive diurnal sleepiness is characterized by an incapacity to stay awake, in favour of sleep occurrence. this sleepiness might be secondary to a sleep disorder; when it is not the case, it is primary hypersomnia (including narcolepsy and idiopathic hypersomnia). to date, objective measures of sleepiness can only be achieved in laboratory. subjective techniques as scales and questionnaires are highly sensitive to inter-individual differences and cannot constitute a reliable diagnosis tool of sleepiness. recent studies suggested that some salivary biomarkers are sensitive to sleep characteristics and thus, may allow the objective and easy evaluation of sleepiness. the objective of the study is to explore the usability of salivary biomarkers (a-amylase and oxalate) as a new non-invasive technique to evaluate sleepiness and to diagnose primary hypersomnia in children. the hypothesis of this study is that there will be a modification of salivary biomarkers concentrations with the variations of diurnal sleepiness.


Eligibility criteria:
inclusion criteria: * children with excessive diurnal sleepiness hospitalized for an evaluation of hypersomnia symptoms * age\> 6 years old and \<18 years old * non opposition by both parents exclusion criteria: * opposition of the child or parents to participate * patients under measure of deprivation of rights and liberty

Keywords: excessive diurnal sleepiness salivary biomarkers children, a-amylase oxalate hypersomnia sleep
effects of progressive muscle relaxation exercises during pregnancy.

Conditions: Lumbopelvic Pain; Insomnia

Summary: lumbopelvic pain (lpp) during pregnancy is defined as pregnancy-related low back, or pelvic girdle pain. pregnancy is a significant time for sleep disruptions as well.pmr involves systematically tensing and relaxing different muscle groups in the body, starting from the feet or hands and progressing through the body. this study aims to evaluate the impact of progressive muscle relaxation (pmr) exercises on the alleviation of low back pain and sleeplessness in pregnant women in their pregnancy.

literature suggests that pregnancy involves hormonal and biomechanics adjustments, leading to changes in body systems for a secure fetus development. painful symptoms and sleep disorders are common complaints, often present in the same individual.the exact cause of low back pain during pregnancy is not fully understood, but it is often linked to biomechanical, vascular, and hormonal changes.in the third trimester, 98% of women experience sleep difficulties, primarily caused by backache, urinary frequency, fetal movements, gerd, and leg discomfort. the pmr technique involves deep breathing and progressive relaxation (tense-release) of major muscle groups. the technique promotes systematic relaxation of the major muscle groups of the body with the goal of physical and mental relaxation, reducing the response to stress, reducing skeletal muscle contractions, and decreasing pain sensations.

Eligibility criteria:
inclusion criteria: * pregnant females with age 20-40 years.during second and third trimester with * uncomplicated pregnancies.pregnancy related lbp \>3 on nprs \& insomnia severity index (isi) \>10 score.posterior lumbopelvic pain exclusion criteria: * patients with anterior lumbopelvic pain. * hemodynamically significant heart disease, * restrictive lung disease, * incompetent cervix/cerclage, * multiple gestation at risk for premature labor \& persistent bleeding.

Keywords: lumbopelvic pain insomnia pregnancy progressive muscle relaxation exercises
a rollover study for patients who participated in other romidepsin protocols

Conditions: Lymphoma; Cancer

Summary: this study is intended to provide access to romidepsin for participants who received romidepsin in other trials sponsored by gloucester pharmaceuticals or celgene corporation and for participants whom the investigator feels may benefit from continuing treatment with romidepsin.

participants must have previously participated in a romidepsin study sponsored by gloucester pharmaceuticals or celgene corporation.

Eligibility criteria:
inclusion criteria 1. previously participated in and fulfilled the inclusion and exclusion criteria in one of the romidepsin clinical trials: romi-advm-001 (nct01324310), romi-advm-002 (nct01324323). additional studies added at the discretion of the medical monitor of the study 2. physician believes continued romidepsin treatment is of benefit to participant. 3. understand and voluntarily sign an informed consent document prior to any study related assessments/procedures are conducted. 4. able to adhere to the study visit schedule and other protocol requirements. 5. negative urine or serum pregnancy test for females of child bearing potential; and 6. all females of child bearing potential must use an effective method of contraception (an intrauterine contraceptive device \[iucd\] or double contraceptive method using condoms and a diaphragm plus spermicide) during the treatment period and for at least 1 month thereafter. male participants should use contraception during the treatment period and for at least 3 months thereafter. female participants should avoid the use of estrogen-containing contraceptives, since romidepsin may reduce the effectiveness of estrogen-containing contraceptives. an in vitro binding assay determined that romidepsin competes with β-estradiol for binding to estrogen receptors. exclusion criteria 1. concomitant use of drugs that may cause a significant prolongation of the corrected measurement of the time between the start of cardiac q wave and the end of the t wave (qtc) . 2. concomitant use of cytochrome p 450 3a4 (cyp3a4) strong inhibitors within 1 week of trial medications. 3. concomitant use of therapeutic warfarin due to a potential drug interaction. use of a low dose of warfarin or another anticoagulant to maintain patency of venous access port and cannulas is permitted. 4. prior chemotherapy or radiotherapy or any investigational agent after the last dose of romidepsin from the preceding romidepsin study. 5. participants who are pregnant or breast-feeding.

Keywords: rollover protocol romidepsin gloucester pharmaceuticals celgene corporation continuing treatment
comparing the impact of 2 different techniques in management of hydrosalpinx on pregnancy rates following icsi

Conditions: Hydrosalpinx

Summary: assessment and comparing pregnancy outcomes in hydrosalpinx patients treated by hysteroscopic tubal occlusion and laparoscopic salpingectomy before icsi.

hydrosalpinx has a detrimental effect on the rates of implantation, pregnancy and early pregnancy loss following ivf. a meta-analysis demonstrated that the implantation rate and clinical pregnancy rate decreased by 50% in patients with hydrosalpinx. the negative consequences could be due to embryotoxic properties, a decrease in endometrial receptivity, and hydrosalpinx fluid mechanically flushing the embryo from the uterus. although laparoscopic salpingectomy and laparoscopic proximal ligation increase ongoing pregnancy rates in women with hydrosalpinges, those interventions are invasive and carry anaesthetic and surgical risks, especially in the presence of extensive adhesions, often seen in women with hydrosalpinges. in view of the possible adverse effects of laparoscopic surgery, an alternative less-invasive treatment for hydrosalpinges prior to ivf would be useful. the effectiveness of hysteroscopic tubal occlusion when compared with salpingectomy has not been established. randomized clinical trials comparing both procedures prior to ivf are lacking. the present study was designed to compare hysteroscopic tubal occlusion and laparoscopic salpingectomy in the treatment of hydrosalpinges prior to ivf. this study hypothesized that in women scheduled for ivf/icsi hysteroscopic proximal occlusion of hydrosalpinges would be non-inferior to laparoscopic salpingectomy in terms of ongoing pregnancy rates following ivf/icsi.

Eligibility criteria:
inclusion criteria: * primary or secondary infertility cases * unilateral or bilateral hydrosalpinx proved by hsg (hystersalpingogram) or by tvus(transvaginal ultrasound) . exclusion criteria: * uterine factor of infertility * male factor of infertility * preexisting ovarian pathology * presence of septic focus * medical or surgical conditions that contraindicated pregnancy
hypnotherapy in patients with chest pain & unobstructed coronaries

Conditions: Chest Pain; Unobstructed Coronary Arteries

Summary: this study will investigate whether clinical hypnotherapy can effectively treat chest pain symptoms, improve emotional wellbeing and quality of life in postmenopausal women with chest pain and coronary arteries without any narrowings. the diagnosis of chest pain with 'normal' coronary arteries is found in 25% of patients undergoing investigation of chest pain using coronary angiography (when dye is injected into the coronary arteries whilst xray pictures are taken), and the majority of these patients are postmenopausal women. often there is no obvious physical cause. despite symptoms being treated using conventional drugs, and life expectancy is not affected, many patients continue to suffer from debilitating chest pain symptoms, frequently resulting in visits to hospital, increased psychological illness and poor quality of life. the investigators are interested in finding ways of improving not only chest pain symptoms but also psychological wellbeing and quality of life in these patients. previous studies of ours have found improvement in these patients after taking part in a support group, and using a relaxation technique called autogenic training. recently the investigators conducted a pilot study which showed a favourable effect of hypnotherapy on physical ability, well-being and quality of life. the investigators would now like to extend this study, performing a larger randomised, controlled trial. the investigators hypothesise that hypnotherapy will beneficially affect symptoms and quality of life in patients with cardiac syndrome x.


Eligibility criteria:
inclusion criteria: * history of chest pain for ≥ 2 years * ≥ 2 episodes chest pain per week * angiographically smooth epicardial coronary arteries * willing to give written informed consent exclusion criteria: * any epicardial coronary atheroma on angiography of the coronary arteries * left ventricular hypertrophy or dysfunction (clinical/ecg/echo/cxr) * previous hypnotherapy for chest pain symptoms * participation in research project within previous 60 days * unwilling to give written informed consent
a three-year behavioral treatment of obese children

Conditions: Childhood Obesity

Summary: the prevalence of overweight and obesity among children and adolescents has reached epidemic proportions worldwide. among swedish 10-year old children 15-20% are overweight and 3-5% are obese. the probability that an obese child becomes an obese adult is very high. this chronic disease requires lifetime treatment. the standard treatment of childhood obesity involves behavioural interventions focused on eating habits and physical activity. studies often include small study samples, the absence of control groups and short treatments times. several long-term follow-up studies of shorter interventions are available. the results from these studies are disappointing since the number of children who are "cured" i.e., have become non-obese is low. thus, effective treatments are currently lacking.the national childhood obesity center treats children in a university hospital setting. the children are enrolled from the catchment areas of the hospital as well as the rest of sweden. treatment alternatives include behavioural treatment (individual and group), low and very low calorie diet, pharmacological and surgical treatment. patients treated with surgical and pharmacological methods safety is ensured using these treatments exclusively in controlled studies. the clinic was the first in sweden with this wide range of treatment options. boris is a national health care quality register for childhood obesity, supervised by the swedish association of local authority and regions.

the primary aim of this study was to compare treatment effects (changes in bmi sds) during the first three years of behavioral treatment in relation to age at start of treatment. the secondary aim was to evaluate specific factors of importance (gender, heredity, parental weight status, socioeconomic factors and age at obesity onset) for treatment effects. the third aim was to investigate factors correlated to drop out. this is a longitudinal study of all patients referred to national childhood obesity center between january 1997 and december 2004. only patients with behavioral treatment were included. patients with other treatments (vlcd/lcd, drugs and surgery) and other diagnoses (syndromes, craniopharyngioma, mb down, myelomeningocele, various types of mental and psychological disorders) and children \ 17 year at inclusion were excluded. the remaining children were divided into three age groups of obese children depending of age at onset of obesity treatment (6-9, 10-13 and 14-16year). all patient data were registered in the boris nationwide childhood obesity database.

Eligibility criteria:
inclusion criteria: * all children treated with behavioral treatment at the national childhood obesity center stockholm between january 1998 - december 2004. * classified as obese by using the tim cole standard. exclusion criteria: * children with obesity together with other diagnosis * children with other treatment like pharmacological, low calorie diets and surgery

Keywords: childhood obesity age-dependent long-term treatment bmi sds dropouts
unilateral neck radiotherapy in head and neck cancer

Conditions: Head and Neck Neoplasms

Summary: patients with head and neck cancer typically undergo a surgical procedure to remove the lymph nodes that could contain disease on both sides of the neck. after surgery, radiotherapy is given (with or without chemotherapy) to the area that underwent surgery and both sides of the neck, even if disease was only found on one side. giving radiotherapy to both sides of the neck commonly results in high rates of side effects, which in turn affects patient quality of life. there is growing evidence from some other studies that support the safety of omitting radiotherapy after surgery in the side of the neck with no disease. with this study, the investigators are hoping to justify its routine use and, if successful, the standard of care could be to receive radiation on only one side of the neck instead of both sides. this could alleviate the extent of some side effects and improve patient quality of life. participants will be randomized into one of the following groups to receive radiotherapy as follows: arm 1 (non-experimental intervention): standard intervention: radiotherapy to both sides of the neck. treatment will begin a maximum of 8 weeks from the surgery date. arm 2 (experimental intervention): radiotherapy to one side of the neck. treatment will begin a maximum of 8 weeks from the surgery date.


Eligibility criteria:
inclusion criteria: patients with squamous cell carcinoma of the head and neck undergoing primary surgical management are eligible to participate if they meet the following eligibility criteria: * age ≥18 * primary site of disease in the oral cavity, oropharynx, larynx, or hypopharynx. * squamous cell carcinoma confirmed by histology. * bilateral modified radical or selective neck dissections carried out as part of primary surgery, with \>= 10 lymph nodes removed from the contralateral neck * the contralateral neck is pathologically negative * pre-surgical fdg-pet/ct scan did not show any clinically involved contralateral neck nodes. * patients must have the ability to read, understand, and sign an informed consent and must be willing to comply with study treatment and follow-up. exclusion criteria: * previous radiation to the head and neck area * pregnancy * other contraindications to radiation treatment (e.g. severe connective tissue disease).

Keywords: radiotherapy
studies of patients with skin disease, patients with neurological degenerations, and normal volunteers

Conditions: Healthy; Muscular Dystrophy; Retinal Degeneration; Skin Diseases; Virus Diseases

Summary: it is proposed that patients with skin disease due to presumed immunologic, genetic or viral-induced abnormalities, patients with neurological degenerations, and normal controls be evaluated with various in vitro studies of immunologic, genetic, and virologic function. this is to include studies of peripheral blood (cells and serum) as well as studies of skin obtained with a biopsy instrument. in addition, studies of gastrointestinal function will be performed where appropriate.

it is proposed that patients with skin disease due to presumed immunologic, genetic or viral-induced abnormalities, patients with neurological degenerations, and normal controls be evaluated with various in vitro studies of immunologic, genetic, and virologic function. this is to include studies of peripheral blood (cells and serum) as well as studies of skin obtained with a biopsy instrument. in addition, studies of gastrointestinal function will be performed where appropriate.

Eligibility criteria:
patients with skin diseases of presumed genetic, immunologic, or virologic origin are eligible. patients with neurological degenerations are eligible, including patients with inflammatory, neoplastic and viral skin diseases and also heterozygous carriers of such inherited diseases. volunteers without skin diseases are eligible, except children.

Keywords: genetic evaluation immunologic evaluations inflammatory skin disease muscular dystrophies neoplastic skin diseases neuronal degenerations retinal degenerations viral diseases
upper versus lower limb exercises on intermittent claudication in diabetic patients

Conditions: Intermittent Claudication

Summary: sixty patients with intermittent claudication and type 2 diabetes mellitus. their age will ranged from 45-55 years old. they recruited from internal department at damanhour medical national institute (dmni), damanhour, beheira governorate, egypt. patients randomly assigned into three equal groups: group (a): upper limb exercises group consist of 20 patients. they received arm cranking exercise three times per week for three consecutive months plus routine physiotherapy program. group (b): lower limb exercises group consist of 20 patients. they received bicycling exercise three times per week for three consecutive months plus routine physiotherapy program. group (c): the control group consisted of 20 patients. they received only routine physiotherapy program.

1. subjects: sixty patients with intermittent claudication and type 2 diabetes mellitus. their age ranged from 45-55 years old. they recruited from internal department at damanhour medical national institute (dmni), damanhour, beheira governorate, egypt. patients randomly assigned into three equal groups: group (a): upper limb exercises group consist of 20 patients. they received arm cranking exercise three times per week for three consecutive months plus routine physiotherapy program. group (b): lower limb exercises group consist of 20 patients. they received bicycling exercise three times per week for three consecutive months plus routine physiotherapy program. group (c): the control group consisted of 20 patients. they received only routine physiotherapy program. 2. equipment: measurement equipment: 1. the treadmill: all patients were tested maximum walking distance and pain free walking distance by walking in the treadmill. 2. ankle/brachial indices (abi) doppler ultrasound machine 3. all patients were tested hba1c before and after the treatment in medical analysis lab department at damanhour medical national institute (dmni). therapeutic equipment: 1. the arm crank ergometer 2. bicycle ergometer

Eligibility criteria:
inclusion criteria: * sixty patients with type 2 diabetes mellitus and intermittent claudication. * patients with diabetes at least 5 years. * both genders were included. * their age will be ranged from 45-55 years old. * patients referred from physician of internal medicine diagnosed as controlled type 2 diabetes (hba1c 7-7.5%) for the previous 3 months. * their body mass index will be ranged from 25.0 to 34.9 kg/m2. exclusion criteria: * pregnant women. * malignancy. * other medical conditions such as uncontrolled hypertension and osteoporosis. * past medical history included conditions that may influence the provision of physiotherapy interventions such as (severe asthma, chronic airflow limitation, bronchiectasis, ankylosing spondylitis or lumbar disc prolapse).
retrospective comparative study on imaging between the bochdalek hernia and congenital diaphragmatic eventration

Conditions: Congenital Diaphragmatic Hernia

Summary: the imaging manifestations of diaphragmatic hernia and diaphragmatic distension were retrospectively analyzed and summarized, combined with the surgical findings, to summarize the differences in indirect signs of diaphragmatic hernia and diaphragmatic distension, so as to achieve the purpose of differential diagnosis.research contents: (1) to summarize the characteristics of indirect imaging signs in patients with diaphragmatic hernia, to sum up the incidence of each sign, to find new signs and the prognosis of each sign; (2) summarize the characteristics of indirect imaging signs in patients with diaphragmatic distension, summarize the incidence of each sign, and search for new signs and the prognosis of each sign; (3) to summarize the differences in indirect signs of diaphragmatic hernia and diaphragmatic distension, as well as the differences in their incidence, and combined with their surgical findings, to summarize their image identification points


Eligibility criteria:
inclusion criteria: * clinical diagnosis of diaphragmatic hernia with surgical treatment * clinical diagnosis of congenital diaphragmatic eventration with surgical treatment exclusion criteria: * diaphragmatic hernia or congenital diaphragmatic eventration without surgical treatment * diaphragmatic hernia or congenital diaphragmatic eventration without imaging examination
hormone deficiency after brain injury during combat

Conditions: Traumatic Brain Injury; Hypopituitarism

Summary: we would like to ascertain the prevalence of hypopituitarism after combat-related tbi. this will lead to enhanced awareness, recognition, and treatment of hypopituitarism, which can have life-saving ramifications and enhance quality of life and rehabilitation efforts in our combat veterans.

the prevalence of hypopituitarism after combat-related traumatic brain injury (tbi) is currently unknown. recent civilian data on tbi show the prevalence of any pituitary hormone deficiency is as high as 80% after 12 months. while the military prevalence of hypopituitarism can be extrapolated from civilian data, a major limitation is the notably different mechanism of injury (i.e., blast) for military personnel compared to civilians (i.e., assaults, traffic accidents and falls). little is known about the effect of shockwaves from a blast injury on central nervous system tissue, and due to the unique nature of blast-related tbi, the prevalence of pituitary dysfunction in affected service members may significantly differ from nonmilitary subjects in prior studies.

Eligibility criteria:
inclusion criteria: * combat veterans who are 3 or 6 months post combat-related tbi and age 18yrs or older * must demonstrate capacity for informed consent * must be deers eligible (military healthcare beneficiary) exclusion criteria: * pregnancy (to be assessed by urine hcg) * use of hormonal contraceptives * chronic oral or intravenous glucocorticoids * use of hormonal therapy to include estrogen and testosterone * prior diagnosis of hypopituitarism prior to combat related tbi

Keywords: traumatic brain injury hypopituitarism